




PHARMACEUTICAL 2023

Aptevo Therapeutics Inc.
Rank 149 of 446





PHARMACEUTICAL 2023

Aptevo Therapeutics Inc.
Rank 149 of 446



The relative strengths and weaknesses of Aptevo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptevo Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 143% points. The greatest weakness of Aptevo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 111% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	27,450
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,706
Liabilities, Non-Current	7,535
Other Assets	5,303
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	36,668
Other Revenues	3,114
Property and Equipment	1,462
Research and Development	17,882
Selling, General and Administrative Expense	13,873

Output Variable	Value in 1000 USD
Assets	34,215
Liabilities	16,241
Expenses	31,755
Revenues	3,114
Stockholders Equity	17,974
Net Income	8,027
Comprehensive Net Income	8,027
Economic Capital Ratio	154%